REG - Hemogenyx Pharma Plc - Result of Annual General Meeting

Hemogenyx PharmaceuticalsAnnouncement

27/06/2024 16:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240627:nRSa2254Ua&default-theme=true

RNS Number : 2254U  Hemogenyx Pharmaceuticals PLC  27 June 2024

27 June 2024

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

 

Result of Annual General Meeting

 

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual
General Meeting ("AGM") held earlier today, all resolutions were duly passed
on a show of hands. The numbers of proxy votes for each resolution submitted
prior to the meeting are presented below.

 

Proxy Voting Results

 Ordinary Resolutions                                                            Votes for    % of votes cast for  Votes Against  % of votes cast against  Total votes cast  Total votes cast as % of ISC (1)  Votes with-held (2)
 1. To receive and adopt the Company's annual accounts for the year ended 31     172,981,350  99.89                189,346        0.11                     173,170,696       12.91                             804,255
 December 2023.
 2. To approve the Directors' Remuneration Report which is set out in the 2023   155,914,909  90.14                17,056,623     9.86                     172,971,532       12.89                             1,003,419
 Annual Report and Accounts.
 3. To re-appoint Sir Marc Feldmann as a Director of the Company.                168,819,296  97.51                4,316,573      2.49                     173,135,869       12.90                             839,082
 4. To re-appoint PKF Littlejohn LLP as auditor of the Company to hold office    156,805,252  99.10                1,429,684      0.90                     158,234,936       11.79                             15,740,015
 until the conclusion of the next Annual General Meeting of the Company.
 5. To authorise the Audit Committee to agree  the auditor's remuneration.       157,329,629  90.99                15,576,903     9.01                     172,906,532       12.89                             1,068,419
 6. To authorise the Directors to allot shares pursuant to section 551 of the    153,328,931  88.71                19,513,766     11.29                    172,842,697       12.88                             1,132,254
 Companies Act 2006.
 Special Resolutions                                                             Votes for    % of votes cast for  Votes against  % of votes cast against  Total votes cast  Total votes cast as % of ISC (1)  Votes with-held (2)
 7. To disapply pre-emption rights under section 570 of the Companies Act 2006.  152,661,902  88.30                20,235,808     11.70                    172,897,710       12.89                             1,077,241
 8. To approve for calling of general meetings (other than AGMs) on 14 days'     172,081,747  99.38                1,080,015      0.62                     173,161,762       12.91                             813,189
 notice.

 

(1)        The Company's issued share capital ("ISC") on 25 June 2024,
being the date on which members had to be entered in the register of members
of the Company in order to be entitled to attend and vote at the meeting, was
1,341,815,988 ordinary shares.

(2)        A 'vote withheld' in respect of any resolution is not a vote
in law and is not counted in the calculation of the proportion of the votes
for and against it.

 

A copy of the resolutions passed has been submitted to the National Storage
Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)

 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl

 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGQKOBNPBKDOAB